Patent · US Active

Optimized anti-TL1A antibodies

US10689439B2 · kind B2 · utility

7Cited by
70References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 25, 2019
Grant dateJun 23, 2020
Priority date—
Expiry dateNov 25, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.